<DOC>
	<DOCNO>NCT03022981</DOCNO>
	<brief_summary>This study 2 part : Pharmacokinetics ( PK ) Lead-in Phase Treatment Phase . The primary objective PK Lead-in Phase evaluate steady state PK confirm dose sofosbuvir/velpatasvir ( SOF/VEL ) fixed-dose combination ( FDC ) pediatric participant chronic hepatitis C virus ( HCV ) infection . The primary objective Treatment Phase evaluate safety tolerability SOF/VEL 12 week pediatric participant chronic HCV .</brief_summary>
	<brief_title>Sofosbuvir/Velpatasvir Adolescents Children With Chronic HCV Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Key Chronic HCVinfected , treatmentnaive treatmentexperienced adolescent pediatric individual age 3 &lt; 18 determine Day 1 . Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>